
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis.
Buying $1,000 In CRSP: 5 years ago, an investor could have purchased 47.08 shares of CRISPR Therapeutics at the time with $1,000. This investment in CRSP would have produced an average annual return of 26.03%. Currently, CRISPR Therapeutics has a market capitalization of $4.83 billion.